重组人骨形态发生蛋白诱导异位成骨的病理学观察

目的：本文报告了重组人骨形态发生蛋白－２在小鼠肌肉内诱导异位成骨的生物学作用。结果：植入重组人骨形态发生蛋白－２后１天有间充质细胞向植入区内聚集;５天出现典型的软骨细胞;７天钙化开始;１０天形成雏形的骨髓腔;１４天骨髓腔内出现幼稚的造血细胞;２１￣３０天形成大量网状骨小梁、骨单位,在骨小梁间隙出现骨髓细胞。结论：大肠杆菌表达的重组人骨形态发生蛋白－２具有较强的诱导成骨活性。     

硅藻DNA片段在表达质粒pMZR中再克隆的研究

用部分酶切法切开表达质粒 pMZR 中一个 HindⅢ位点后,插入了一个带 HindⅢ粘性末端的1kb 硅藻 DNA 片段重组 DNA 分子转化 E.coli LE392,对转化子中的重组 DNA 分子用酶切分析后,鉴定了1kb DNA 片段插入 pMZR 的位置。     

重组戊型肝炎疫苗的免疫原性试验

目的　研究重组戊型肝炎疫苗的免疫原性。方法　通过对小鼠、新西兰兔的多点皮内注射及肌肉注射 ,然后测定其抗体效价 ,研究重组戊型肝炎疫苗的性能。结果　小鼠在免疫 7d后开始产生抗体 ,两周抗体阳性率为80 % ,四周抗体阳性率达 10 0 %。新西兰兔从第二周后开始产生抗体 ,第三周达到高峰 ,抗血清在 1∶6 4 0 0稀释度的阳性率达 4 0 %。结论　重组戊型肝炎疫苗免疫动物具有良好的免疫原性 ,为进一步研究开发戊肝疫苗对人体的免疫提供了基础     

高产聚-3-羟基丁酸重组大肠杆菌的筛选

将能以葡萄糖为唯一碳源积累P(3HB)的工程菌进行优化筛选,获得6个较高产的菌株,PHB含量最高为69.1%.经丙酸驯化,虽然没有PHBV的积累,但PHB的量均有增加,最高可达71.13%.另外,抗生素对菌体生长及PHB积累有重要影响.     

Chitotriosidase and gene therapy for fungal infections

Chitotriosidase secreted by activated human macrophages has been implicated in the defence against chitin-bearing pathogens. The antifungal properties of human chitotriosidase were investigated here following retroviral vector-mediated gene transfer of the open reading frame of the chitotriosidase gene into Chinese hamster ovary cells. A chitinase assay confirmed that the engineered cells secreted recombinant chitotriosidase constitutively. Two dimensional gel electrophoresis and western blotting indicated that the recombinant protein is the major, chitin-binding, fifty kilodalton isoform. Culture medium conditioned by the transduced cells inhibited growth of isolates of Aspergillus niger, Candida albicans and Cryptococcus neoformans. Furthermore, longevity was significantly increased in a mouse model of cryptococcosis when cells transduced with the chitotriosidase gene and encapsulated in alginate microspheres were implanted subcutaneously in the animals. Engraftment of microcapsules containing cells transduced with the chitotriosidase gene has the potential to combat infections caused by chitinous pathogens through the prolonged delivery of recombinant chitotriosidase. Received 29 November 2008; received after revision 11 January 2009; accepted 13 January 2009     

美国重组DNA咨询委员会的演变史

 重组DNA技术于1972年诞生于美国高校实验室。重组DNA咨询委员会（简称RAC）问世于1974年，并于2019年退出历史舞台，为美国基因操作技术的风险规制立下了汗马功劳。RAC在美国基因操作技术风险规制中跌宕起伏的演变史，是美国基因操作技术的风险规制由稚嫩逐步走向成熟的印证。通过探究RAC及其监管权是在哪些力量的作用下问世，还原RAC在基因操作技术风险阴霾笼罩下被政府当局质疑能力的历史图景，呈现美国基因治疗的基本规制路径，描述RAC审批首次基因治疗的经过以及RAC在首次基因治疗致死事件中的应对表现，阐述RAC退出历史舞台的过程和缘由，从而描摹一幅美国重组DNA咨询委员会演变历程的脉络图。